Top Markets
Coin of the day
Acticor Biotech SAS Acticor Biotech SAS

Acticor Biotech SAS

ALACT
Peringkat dalam Saham #37014
Acticor Biotech SAS is a clinical-stage biotechnology firm focused on creating... Acticor Biotech SAS is a clinical-stage biotechnology firm focused on creating therapies for the acute phase of thrombotic conditions. The company's lead compound, glenzocimab, is a humanized monoclonal antibody fragment specifically designed to target a particular platelet glycoprotein. Currently, Acticor Biotech is advancing two clinical programs, both in Phase II/III, for the registration of treatments for ischemic stroke. Additionally, it is conducting two other Phase II trials concerning significant cardiovascular emergencies, with anticipated clinical data expected from both its ischemic stroke research and studies related to COVID-19 respiratory distress syndrome. Established in 2013, the company operates from its headquarters in Paris, France.
Harga Saham
$0.25974701
Terakhir disinkronkan: 2025-01-06
Kapitalisasi Pasar
$2.04M
Perubahan (1 hari)
0.74%
Perubahan (1 tahun)
0.00%
Negara
FR
Perdagangan Acticor Biotech SAS (ALACT)

Kategori

Rasio P/S untuk Acticor Biotech SAS (ALACT)
Rasio P/S per September 2026 TTM: 0.00
Menurut laporan keuangan dan harga saham terbaru dari Acticor Biotech SAS, rasio P/S saat ini (TTM) adalah 0.00. Pada akhir 2022, rasio P/S perusahaan adalah 0.00.
Riwayat rasio P/S untuk Acticor Biotech SAS dari 2010 hingga 2026
Rasio P/S pada akhir setiap tahun
Tahun Rasio P/S Mengubah
2026 (TTM) 0.00 0.00%
2023 0.00 0.00%
2022 0.00 0.00%
2021 0.00 0.00%
2020 0.00 0.00%
2019 0.00 -100.00%
2018 432.73 16,252.85%
2017 2.65 56.77%
2016 1.69 23.03%
2015 1.37 16.08%
2014 1.18 -11.28%
2013 1.33 -13.75%
2012 1.54 -29.62%
2011 2.19 -58.15%
2010 5.24 0.00%
Rasio P/S untuk perusahaan sejenis atau pesaing
Perusahaan Rasio P/S Perbedaan Rasio P/S Negara
10.44 -
US
12.01 -
NL
3.76 -
AU
26.12 -
US
- -
CH